Cellular Uptake of the ATSM-Cu(II) Complex under Hypoxic Conditions.


Journal

ChemistryOpen
ISSN: 2191-1363
Titre abrégé: ChemistryOpen
Pays: Germany
ID NLM: 101594811

Informations de publication

Date de publication:
04 2021
Historique:
revised: 08 03 2021
received: 22 02 2021
entrez: 28 4 2021
pubmed: 29 4 2021
medline: 8 9 2021
Statut: ppublish

Résumé

The Cu(II)-diacetyl-bis (N4-methylthiosemicarbazone) complex (ATSM-Cu(II)) has been suggested as a promising positron emission tomography (PET) agent for hypoxia imaging. Several in-vivo studies have shown its potential to detect hypoxic tumors. However, its uptake mechanism and its specificity to various cancer cell lines have been less studied. Herein, we tested ATSM-Cu(II) toxicity, uptake, and reduction, using four different cell types: (1) mouse breast cancer cells (DA-3), (2) human embryonic kidney cells (HEK-293), (3) breast cancer cells (MCF-7), and (4) cervical cancer cells (Hela) under normoxic and hypoxic conditions. We showed that ATSM-Cu(II) is toxic to breast cancer cells under normoxic and hypoxic conditions; however, it is not toxic to normal HEK-293 non-cancer cells. We showed that the Cu(I) content in breast cancer cell after treatment with ATSM-Cu(II) under hypoxic conditions is higher than in normal cells, despite that the uptake of ATSM-Cu(II) is a bit higher in normal cells than in breast cancer cells. This study suggests that the redox potential of ATSM-Cu(II) is higher in breast cancer cells than in normal cells; thus, its toxicity to cancer cells is increased.

Identifiants

pubmed: 33908707
doi: 10.1002/open.202100044
pmc: PMC8080296
doi:

Substances chimiques

Coordination Complexes 0
Copper Radioisotopes 0
Copper Transporter 1 0
Copper-64 0
Organometallic Compounds 0
SLC31A1 protein, human 0
Slc31a1 protein, mouse 0
Thiosemicarbazones 0
copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

486-492

Informations de copyright

© 2021 The Authors. Published by Wiley-VCH GmbH.

Références

Elife. 2017 Oct 19;6:
pubmed: 29049022
Eur J Nucl Med. 1998 Jul;25(7):788-92
pubmed: 9662602
Nucl Med Biol. 1996 Nov;23(8):957-80
pubmed: 9004284
Cancer Res. 1998 Apr 1;58(7):1408-16
pubmed: 9537241
J Nucl Med. 1999 Jan;40(1):177-83
pubmed: 9935074
Nucl Med Biol. 2010 Apr;37(3):237-43
pubmed: 20346863
Biomaterials. 2020 Dec;263:120330
pubmed: 32942127
Cancer Metastasis Rev. 2007 Jun;26(2):225-39
pubmed: 17440684
Nucl Med Biol. 2008 Apr;35(3):273-9
pubmed: 18355682
Clin Cancer Res. 2004 Apr 1;10(7):2245-52
pubmed: 15073099
Radiother Oncol. 1998 Aug;48(2):149-56
pubmed: 9783886
Chemistry. 2019 Jan 2;25(1):221-237
pubmed: 30221802
Br J Radiol. 1953 Dec;26(312):638-48
pubmed: 13106296
Cancer Res. 1996 Oct 1;56(19):4509-15
pubmed: 8813149
Clin Cancer Res. 2006 Sep 15;12(18):5435-41
pubmed: 17000677
Inorg Chem. 2008 May 19;47(10):4338-47
pubmed: 18412332
Semin Nucl Med. 2007 Nov;37(6):451-61
pubmed: 17920352
J Biol Chem. 2007 Mar 23;282(12):8622-31
pubmed: 17229731
ACS Omega. 2019 Jul 17;4(7):12278-12285
pubmed: 31460344
J Radiat Res. 2013 Nov 1;54(6):1078-84
pubmed: 23589026
Inorg Chem. 2019 Oct 21;58(20):13709-13723
pubmed: 31339305
Dalton Trans. 2006 Feb 14;(6):783-94
pubmed: 16437173
Semin Cancer Biol. 2015 Dec;35 Suppl:S25-S54
pubmed: 25892662
Int J Radiat Biol. 2006 Oct;82(10):699-757
pubmed: 17118889
Nucl Med Biol. 1999 May;26(4):351-8
pubmed: 10382836
Radiat Oncol. 2012 Jun 15;7:89
pubmed: 22704363
Front Med (Lausanne). 2015 Aug 24;2:58
pubmed: 26380261
J Inorg Biochem. 2015 Nov;152:20-37
pubmed: 26335599
Annu Rev Physiol. 2008;70:51-71
pubmed: 17850210
J Nucl Med. 1997 Jul;38(7):1155-60
pubmed: 9225812
Front Neurosci. 2019 Jul 25;13:770
pubmed: 31404249
Australas Phys Eng Sci Med. 2019 Dec;42(4):981-993
pubmed: 31520369
PLoS One. 2015 Jun 22;10(6):e0131083
pubmed: 26098420
Hypoxia (Auckl). 2015 Dec 11;3:83-92
pubmed: 27774485
Nanomedicine (Lond). 2019 Apr;14(7):835-850
pubmed: 30875274
Methods Enzymol. 2007;435:297-321
pubmed: 17998060
Cell Death Dis. 2019 Nov 13;10(11):861
pubmed: 31723121
Anal Biochem. 1995 Mar 20;226(1):80-4
pubmed: 7785783
Dalton Trans. 2007 Nov 21;(43):4893-902
pubmed: 17992274
Chem Rev. 2006 Jun;106(6):1995-2044
pubmed: 16771441
Inorg Chem. 2014 Oct 6;53(19):10003-5
pubmed: 25237806
ChemistryOpen. 2021 Apr;10(4):486-492
pubmed: 33908707
Semin Nucl Med. 2001 Oct;31(4):321-9
pubmed: 11710774
Int J Mol Sci. 2020 May 31;21(11):
pubmed: 32486510
Cancer Sci. 2009 Aug;100(8):1366-73
pubmed: 19459851

Auteurs

Gulshan R Walke (GR)

Department of Chemistry, Faculty of Exact Sciences, and the, Institute for Nanotechnology and advanced materials (BINA), Bar-Ilan University, 5290002, Ramat-Gan, Israel.

Shelly Meron (S)

Department of Chemistry, Faculty of Exact Sciences, and the, Institute for Nanotechnology and advanced materials (BINA), Bar-Ilan University, 5290002, Ramat-Gan, Israel.

Yulia Shenberger (Y)

Department of Chemistry, Faculty of Exact Sciences, and the, Institute for Nanotechnology and advanced materials (BINA), Bar-Ilan University, 5290002, Ramat-Gan, Israel.

Lada Gevorkyan-Airapetov (L)

Department of Chemistry, Faculty of Exact Sciences, and the, Institute for Nanotechnology and advanced materials (BINA), Bar-Ilan University, 5290002, Ramat-Gan, Israel.

Sharon Ruthstein (S)

Department of Chemistry, Faculty of Exact Sciences, and the, Institute for Nanotechnology and advanced materials (BINA), Bar-Ilan University, 5290002, Ramat-Gan, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH